Stock Track | ADMA Biologics Soars 5.20% Intraday on $125 Million Share Repurchase Announcement with JPMorgan

Stock Track
03/02

ADMA Biologics' stock surged 5.20% during intraday trading on Monday, following the company's announcement of a significant capital return initiative.

The biopharmaceutical company revealed a planned $200 million share repurchase program for 2026, including a $125 million accelerated share repurchase agreement with JPMorgan. This initiative is part of the company's existing program authorizing up to $500 million in repurchases.

ADMA's President and CEO Adam Grossman stated that the company views its common stock as "meaningfully undervalued" and represents "the most compelling near-term capital deployment opportunity." The announcement reflects management's confidence in ADMA's strong financial position, durable free cash flow profile, and long-term growth trajectory.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10